SPYRE INFOSTRUCTURE
Spyre Infostructure is a technology company focused on innovation development.
SPYRE INFOSTRUCTURE
Industry:
Biotechnology Information Technology
Founded:
1996-10-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.spyre.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Euro Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Font Awesome Facebook Sharer Cloudflare CDN
Similar Organizations
Bontesoft
Bontesoft is a technology company for innovative business development.
Codeister Technologies
Codeister Technologies is a young & vibrant technology company focused on innovative product development in various domains.
DryLab
DryLab is a science and technology company for food dehydration.
Glocalidad
All about technology, science and national innovation will find it here.
Odyssian Technology
Odyssian Technology is a high technology company focused on technology innovation and creative product development.
OFTN
A tech company
PlatforMedia
PlatforMedia is a technology company with a focus on innovation and unique projects.
VetoSynth
VetoSynth is a technology company focused on developing innovative products in the consumer packaged goods space.
Current Employees Featured
Official Site Inspections
http://www.spyre.com Semrush global rank: 3.49 M Semrush visits lastest month: 3.75 K
- Host name: 147.75.40.150
- IP address: 147.75.40.150
- Location: Amsterdam Netherlands
- Latitude: 52.2832
- Longitude: 4.7521
- Timezone: Europe/Amsterdam
- Postal: 1119
More informations about "Spyre Infostructure"
Spyre Therapeutics
Engineering for new heights in the treatment of Inflammatory Bowel Disease. Spyre Therapeutics is developing potential best-in-class antibodies, rational therapeutic combinations, and precision immunology approaches with the goal …See details»
Spyre Therapeutics, Inc. | Investor Relations - Company Overview
Dec 2, 2024 Spyre Therapeutics is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody …See details»
About | Spyre Therapeutics
Spyre is focused on developing next generation therapeutics for people living with IBD, including ulcerative colitis (UC) and Crohn’s disease (CD). Our portfolio of novel and proprietary monoclonal antibody product candidates has the …See details»
Spyre Therapeutics - Crunchbase Company Profile
Organization. Spyre Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Spyre Therapeutics …See details»
Chief Executive Officer - Spyre
Cameron Turtle, DPhil, is Chief Executive Officer. He is an experienced leader in building, financing, and shaping biopharma organizations from preclinical development to late-stage clinical trials and commercialization.See details»
Spyre Therapeutics, Inc. (SYRE) - Yahoo Finance
See the company profile for Spyre Therapeutics, Inc. (SYRE) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Spyre Therapeutics, Inc.
Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, …See details»
Spyre Therapeutics - Leadership Team - The Org
The Leadership Team at Spyre Therapeutics is responsible for setting the strategic direction of the company, ensuring regulatory and legal compliance, overseeing financial health, and …See details»
Spyre Therapeutics, Inc. | Investor Relations - Press Releases
WALTHAM, Mass., Nov. 27, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) (the "Company" or "Spyre"), a development-stage biotechnology company, today …See details»
Join Us | Spyre Therapeutics
At Spyre, we are guided by our mission to develop potentially best-in-class therapeutics for people living with IBD. We are a collaborative interdisciplinary team, united in our drive to innovate and dedicated to enhancing patient lives. …See details»
Spyre Therapeutics Inc, SYRE:NSQ profile - FT.com - Financial Times
Nov 22, 2024 Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, …See details»
Spyre Infostructure - Crunchbase Company Profile & Funding
Spyre Infostructure is a technology company focused on innovation development. Toronto, Ontario, Canada; 1-10; Private; www.spyre.com ; 874,675See details»
Spyre Celebrates 20 Years – Spyre Solutions
Spyre Solutions is very excited to be celebrating our 20 year anniversary in 2020! ... From an early beginning, you encouraged Spyre to grow to be Canada’s trusted ERP Solution …See details»
Spyre Therapeutics, Inc. | Investor Relations - Press Releases
Jun 22, 2023 spyre, its affiliates, their respective officers, directors, employees, agents, suppliers, or licensors (collectively, the “spyre parties“) make no warranties or representations …See details»
Spyre Solutions
Spyre Solutions is Canada’s leading PeopleSoft application software solution provider, with offices in Alberta and Ontario, serving clients in Canada, the United States and Europe for nearly 25 …See details»
Chief Financial Officer - Spyre
Prior to Spyre, he served as the Chief Financial Officer of Arcutis Biotherapeutics, Inc., where he helped lead Arcutis through a successful initial public offering, several further equity and debt …See details»
Unilever | Spyre Group
Unilever's partnership with Spyre Group enabled them to leverage the entrepreneurial ecosystem and identify innovative solutions that addressed their specific challenges. Through a …See details»
Spyre Therapeutics Reports First Quarter 2024 Financial Results …
May 9, 2024 About Spyre Therapeutics Spyre Therapeutics is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining …See details»
Spyre Therapeutics Announces Positive Interim Results from Phase …
Nov 12, 2024 Spyre will host a conference call and webcast today, November 12, 2024, ... that is automatically assigned to your computer whenever you log on to your internet service …See details»
Spyre Therapeutics Announces Expected Acceleration of SPY003 …
Oct 14, 2024 SPY003, a novel half-life extended IL-23p19 monoclonal antibody (mAb), with first-in-human dosing now expected first quarter 2025. New data on SPY003 presented at UEGW …See details»